Rhinovirus diagnostics market seen growing 8.2% annually through 2030

The rhinovirus diagnostics market is projected to climb from $1.58 billion in 2025 to $2.33 billion by 2030, driven by demand for faster respiratory testing and broader use of molecular tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Rhinovirus diagnostics help clinicians identify the virus behind many common cold and respiratory illness cases faster. - The market’s expansion reflects rising demand for accurate testing, especially as respiratory disorders and healthcare spending increase. - The shift toward rapid, point-of-care and multiplex testing could change how respiratory infections are detected and managed.

What happened: - The rhinovirus diagnostics market is projected to grow from $1.58 billion in 2025 to $1.71 billion in 2026. - The market is forecast to reach $2.33 billion by 2030, implying an 8.2% CAGR. - The Business Research Company released the forecast in its "Rhinovirus Diagnostics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report was dated July 22, 2026. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Historical growth has been supported by higher rates of common colds and respiratory infections worldwide. - Wider adoption of molecular diagnostic methods has helped expand viral detection. - Better hospital laboratory testing facilities have supported market growth. - Traditional virus culture techniques have limitations that favor newer diagnostic approaches. - Greater awareness of early infectious disease diagnosis has added to demand. - The forecast period is being shaped by demand for rapid point-of-care diagnostic tests. - AI-driven diagnostic interpretation tools are becoming a growth driver. - Multiplex testing panels that detect multiple respiratory pathogens are gaining traction. - Investment in infectious disease monitoring systems is increasing. - Personalized and precision medicine approaches for respiratory conditions are contributing to demand. - Emerging trends include AI-enhanced rapid respiratory pathogen identification. - Broader use of multiplex PCR respiratory virus panels is expected. - Point-of-care rhinovirus diagnostic devices are gaining ground. - Cloud-based infectious disease surveillance platforms are expanding. - Highly sensitive molecular assays for early detection are under development. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - Rising respiratory disease burden appears to be pushing labs and providers toward faster, more precise testing. - The combination of AI, multiplex panels and cloud-based surveillance suggests diagnostics are moving beyond single-pathogen detection toward broader respiratory monitoring. - The growth outlook also points to continued investment in lab infrastructure and digital interpretation tools.

What's next: - More hospitals and care settings are likely to adopt rapid, point-of-care rhinovirus tests. - Multiplex PCR panels and molecular assays are expected to play a larger role in routine respiratory testing. - The fastest gains may come from markets where infectious disease surveillance and diagnostic infrastructure are still expanding. - The Business Research Company is offering a free sample report and a full market report through its website.